Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry.
about
Psoriasis registries worldwide: systematic overview on registry publications.Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis.Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest.Providing Guidance for Patients With Moderate-to-Severe Psoriasis Who Are Candidates for Biologic Therapy: Role of the Nurse Practitioner and Physician Assistant.Tofacitinib for the treatment of moderate-to-severe psoriasis.Apremilast for the treatment of psoriasis.A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast.Biologics and dermatology life quality index (DLQI) in the Australasian psoriasis population.Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries.Effectiveness and safety of Methotrexate in psoriasis: an eight-year experience with 218 patients.Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis.A new class of biologic agents facing the therapeutic paradigm in psoriasis: anti-IL-23 agents.Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis.
P2860
Q30251454-7E57E777-90A1-46C0-8958-30976DED5E6DQ34520662-134EE48D-2778-445E-BE2C-FAC1008954B2Q36275101-CA769D9D-9A9B-4EA5-A8D7-21FC87EDB014Q36628064-28F8EF3D-356D-4156-9C82-29D8FEF0862FQ38349779-24CA3A32-2FD6-4D36-8969-0979B1213C7FQ38561061-70C85482-1053-4CD4-BA9B-EC1E9963086CQ38675867-F141FACC-E422-4F85-9977-F19A20D004EFQ38794282-C97FE6CB-1D42-4469-8A37-653ED2F4F400Q38970218-C6EA3EBE-475A-4301-865A-01DED3C3D3E3Q39046392-B25932AB-4B19-4E94-8D00-AE2738CE5CA3Q39361316-E1C94DF9-DA73-45C9-B3FC-5335AD4AA868Q47657450-C30DBAEB-8B3C-4581-94D1-6A43C5D09BAFQ47671991-4E0DEF6E-48E2-49CB-8EC0-9C27DCFE0C66
P2860
Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Risk of adverse events in psor ...... s of the Biobadaderm registry.
@en
Risk of adverse events in psor ...... s of the Biobadaderm registry.
@nl
type
label
Risk of adverse events in psor ...... s of the Biobadaderm registry.
@en
Risk of adverse events in psor ...... s of the Biobadaderm registry.
@nl
prefLabel
Risk of adverse events in psor ...... s of the Biobadaderm registry.
@en
Risk of adverse events in psor ...... s of the Biobadaderm registry.
@nl
P2093
P2860
P50
P356
P1476
Risk of adverse events in psor ...... s of the Biobadaderm registry.
@en
P2093
BIOBADADERM Study Group
C Ferrandiz
E Herrera-Ceballos
F Vanaclocha Sebastián
G Carretero
I Belinchón
J L Sánchez-Carazo
J M Carrascosa
P2860
P304
P356
10.1111/JDV.12492
P577
2014-03-31T00:00:00Z